
Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at "Site 3", blocking the interaction with the signaling co-receptor gp130.
Models, Molecular, Binding Sites, Hybridomas, Sequence Homology, Amino Acid, Interleukin-6, Molecular Sequence Data, Antigen-Antibody Complex, Antibodies, Monoclonal, Humanized, Crystallography, X-Ray, Antibodies, Neutralizing, Arthritis, Experimental, Rats, Immunoglobulin Fab Fragments, Macaca fascicularis, Report, Interleukin-6 Inhibitors, Cytokine Receptor gp130, Animals, Humans, Female, Amino Acid Sequence
Models, Molecular, Binding Sites, Hybridomas, Sequence Homology, Amino Acid, Interleukin-6, Molecular Sequence Data, Antigen-Antibody Complex, Antibodies, Monoclonal, Humanized, Crystallography, X-Ray, Antibodies, Neutralizing, Arthritis, Experimental, Rats, Immunoglobulin Fab Fragments, Macaca fascicularis, Report, Interleukin-6 Inhibitors, Cytokine Receptor gp130, Animals, Humans, Female, Amino Acid Sequence
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 82 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
